Wed, Apr 23, 2014, 12:15 PM EDT - U.S. Markets close in 3 hrs 45 mins


% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

factman777 2 posts  |  Last Activity: Mar 20, 2014 5:09 PM Member since: Oct 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I left a message yesterday and he called me back this morning.

    He only provides information that is already public which is of course is what he is supposed to do. However, he did say that they have used Root Cause Analysis (RCA) to identify the manufacturing issues with respect to the scaffold and that they are very confident that they will be enrolling subjects in the second quarter of 2014.

    From Wikipedia…

    Root cause analysis (RCA) is a method of problem solving that tries to identify the root causes of faults or problems. RCA practice tries to solve problems by attempting to identify and correct the root causes of events, as opposed to simply addressing their symptoms. Focusing correction on root causes has the goal of preventing problem recurrence.

    Sentiment: Strong Buy

  • Folks, it’s clear and obvious that this human clinical study of its scaffold device is going happen. The rest of the IRB approvals are going to happen and they will get the manufacturing issues with respect to the scaffold corrected.

    Is a time frame of a couple months a long time in the world of biotech investing. I think NOT.

    Great buying opportunity for existing shareholders to add to their positions and for new investors to initiate positions. When they announce their first patient this stock is going over $4 easily.

    Don’t forget that this is an open label clinical trial so results can be reported during the trial of each patient. If even 10% of the nerve tissue can be preserved, it can make a world of difference to the patient’s outcome and quality of life. Even something so small as a patient who is totally paralyzed vs. one who can move a finger to press buttons on a wheel chair is a huge difference … let alone walk across the room as all the African Green monkeys could afterwards.

    Remember, NVIV has tested over 40 paralyzed African Green monkeys and every one of them was able to run again within 3 weeks. These monkeys are excellent models for humans with a genomic similarity in excess of 98%, and the neuro-physiological characteristics of how the spinal cord works in humans as compared to these African Green monkeys is nearly identical.

    Enough said. Time yo buy more share of NVIV.

    Sentiment: Strong Buy

1.52-0.03(-1.94%)11:57 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.